A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects

Journal of Clinical Pharmacology

Volumn 57, Issue 5, 2017, Pages 627-639

  Donovan, Joanne M ^a   Zimmer, Michael ^a   Offman, Elliot ^b   Grant, Toni ^b   Jirousek, Michael ^a  

^a Catabasis Pharmaceuticals Inc   (United States)

^b CELERION   (United States)

Author keywords

CAT 1004; Duchenne muscular dystrophy; edasalonexent; inflammation; NF B; pharmacokinetics

Indexed keywords

DOCOSAHEXAENOIC ACID; DYSTROPHIN; EDASALONEXENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLACEBO; SALICYLIC ACID; SALICYLURIC ACID; ARACHIDONIC ACID DERIVATIVE; PROTEOME; SALICYLAMIDE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; DYSPEPSIA; FEMALE; FOOD DRUG INTERACTION; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HEADACHE; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WHEEZING; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADULT; ARACHIDONIC ACIDS; FEMALE; GENE EXPRESSION; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MUSCULAR DYSTROPHY, DUCHENNE; NF-KAPPA B; PROTEOME; SALICYLAMIDES; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 85010850378     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.842     Document Type: Article

References (44)

1. Emery AE. Population frequencies of inherited neuromuscular diseases—a world survey. Neuromusc Disord. 1991;1(1):19–29.
2. Porter JD, Merriam AP, Leahy P, Gong B, Khanna S. Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice. Hum Mol Genet. 2003;12(15):1813–1821.
3. Chen YW, Nagaraju K, Bakay M, et al. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology. 2005;65(6):826–834.
4. Rosenberg AS, Puig M, Nagaraju K, et al. Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med. 2015;7(299):299rv4.
5. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2008(1):CD003725.
6. Schram G, Fournier A, Leduc H, et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol. 2013;61(9):948–954.
7. Ricotti V, Ridout DA, Scott E, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry. 2013;84(6):698–705.
8. Hanaoka BY, Peterson CA, Horbinski C, Crofford LJ. Implications of glucocorticoid therapy in idiopathic inflammatory myopathies. Nat Rev Rheumatol. 2012;8(8):448–457.
9. Schakman O, Gilson H, Kalista S, Thissen J. Mechanisms of muscle atrophy induced by glucocorticoids. Horm Res. 2009;72(suppl 1):36–41.
10. Mourkioti F, Rosenthal N. NF-kappaB signaling in skeletal muscle: prospects for intervention in muscle diseases. J Mol Med (Berl). 2008;86(7):747–759.
11. Monici MC, Aguennouz M, Mazzeo A, Messina C, Vita G. Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology. 2003;60(6):993–997.
12. Shin J, Tajrishi MM, Ogura Y, Kumar A. Wasting mechanisms in muscular dystrophy. Int J Biochem Cell Biol. 2013;45(10):2266–2279.
13. Acharyya S, Villalta SA, Bakkar N, et al. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest. 2007;117(4):889–901.
14. Li H, Malhotra S, Kumar A. Nuclear factor-kappa B signaling in skeletal muscle atrophy. J Mol Med (Berl). 2008;86(10):1113–1126.
15. Peterson JM, Bakkar N, Guttridge DC. NF-kappaB signaling in skeletal muscle health and disease. Curr Top Dev Biol. 2011;96:85–119.
16. Lu A, Proto JD, Guo L, et al. NF-kappaB negatively impacts the myogenic potential of muscle-derived stem cells. Mol Ther. 2012;20(3):661–668.
17. Mourkioti F, Kratsios P, Luedde T, et al. Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J Clin Invest. 2006;116(11):2945–2954.
18. Kumar A, Boriek AM. Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J. 2003;17(3):386–396.
19. Hu X, Blemker S. Musculoskeletal simulation can help explain selective muscle degeneration in Duchenne muscular dystrophy. Muscle Nerve. 2015;52:174–182.
20. Vu CB, Bemis JE, Benson E, et al. Synthesis and characterization of fatty acid conjugates of niacin and salicylic acid. J Med Chem. 2016;59(3):1217–1231.
21. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998;396(6706):77–80.
22. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265(5174):956–959.
23. Cai D, Frantz JD, Tawa NE Jr, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004;119(2):285–298.
24. Rainsford K. Side effects and toxicology of the salicylates. In:Rainsford K, Ed. Aspirin and related drugs. Boca Raton, FL: CRC Press; 2004:367–554.
25. Williams-Bey Y, Boularan C, Vural A, et al. Omega-3 free fatty acids suppress macrophage inflammasome activation by inhibiting NF-kappaB activation and enhancing autophagy. PLoS One. 2014;9(6):e97957.
26. Zwart SR, Pierson D, Mehta S, Gonda S, Smith SM. Capacity of omega-3 fatty acids or eicosapentaenoic acid to counteract weightlessness-induced bone loss by inhibiting NF-kappaB activation: from cells to bed rest to astronauts. J Bone Mineral Res. 2010;25(5):1049–1057.
27. Vedin I, Cederholm T, Freund-Levi Y, et al. Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One. 2012;7(4):e35425.
28. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002;21(6):495–505.
29. Bouwens M, van de Rest O, Dellschaft N, et al. Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am J Clin Nutr. 2009;90(2):415–424.
30. Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142(5):687–698.
31. Hammers DW, Sleeper MM, Forbes SC, et al. Disease modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle. JCI Insight. In press.
32. Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev. 2007;65(12 Pt 2):S152–156.
33. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014;13(6):465–476.
34. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–1801.
35. Goldfine AB, Fonseca V, Jablonski KA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010;152(6):346–357.
36. Weldon SM, Mullen AC, Loscher CE, Hurley LA, Roche HM. Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J Nutr Biochem. 2007;18(4):250–258.
37. Duthie GG, Wood AD. Natural salicylates: foods, functions and disease prevention. Food Funct. 2011;2(9):515–520.
38. Wood A, Baxter G, Thies F, Kyle J, Duthie G. A systematic review of salicylates in foods: estimated daily intake of a Scottish population. Mol Nutr Food Res. 2011;55 Suppl 1:S7–S14.
39. Needs CJ, Brooks PM. Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet. 1985;10(2):164–177.
40. Zuijdgeest-van Leeuwen SD, Dagnelie PC, Rietveld T, van den Berg JW, Wilson JH. Incorporation and washout of orally administered n-3 fatty acid ethyl esters in different plasma lipid fractions. Br J Nutr. 1999;82(6):481–488.
41. Donovan J, Sweeney H, Vandenborne K, et al. CAT-1004, an oral agent targeting NF-κB in development for treatment of Duchenne muscular dystrophy: Phase 1/2 study design. Neuromusc Disord. 2015;25:S262.
42. Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50(4):477–487.
43. Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74(5):637–647.
44. Fiorillo AA, Heier CR, Novak JS, et al. TNF-alpha-induced microRNAs control dystrophin expression in Becker muscular dystrophy. Cell Rep. 2015;12(10):1678–1690.